Fig. 3: AQB inhibits BRCA1 expression by upregulating ATF3. | Cell Death & Disease

Fig. 3: AQB inhibits BRCA1 expression by upregulating ATF3.

From: AQB improves carboplatin sensitivity in endometrial cancer through dual DNA repair modulation: suppression of the p21-E2F1-RAD51 and ATF3-HDAC1-BRCA1 signaling

Fig. 3

A mRNA levels of BRCA1 in EC cells. B GO analysis of DEGs between AQB and control groups. C mRNA levels of ATF3 in EC cells. D Western blot analysis of ATF3, HDAC1 and BRCA1. A, C, D HEC-1A cells were treated with various concentrations of AQB (0, 40, 80, 120, and 160 μM) for 48 h, while HEC-1B cells were treated with AQB (0, 30, 60, 90, and 120 μM) for 48 h. E ChIP analysis of the ATF3 promoter region in EC cells using an anti-H3K27me3 antibody. F Protein expression levels of BRCA1 and HDAC1 after ATF3 knockdown in the HEC-1A cells. G ChIP analysis of the BRCA1 promoter region in EC cells using an anti-ATF3 antibody. H Co-IP assays were performed with anti-ATF3 antibody, followed by immunoblotting with HDAC1 antibodies. I, J ChIP analysis of the BRCA1 promoter region in EC cells using anti-HDAC1 and anti-H3K27ac antibodies. The data are expressed as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns not significant.

Back to article page